A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma - Concepedia

Concepedia

Publication | Open Access

A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

DOI Full Paper Access

149

Citations

34

References

2011

Year

Thomas Eigentler, Benjamin Weide, Filippo de Braud, Gianluca Spitaleri, Antonella Romanini, Annette Pflugfelder, Reinerio González‐Iglesias, Annaelisa Tasciotti, Leonardo Giovannoni, Kathrin Schwager,

Clinical Cancer Research

Abstract

The repeated administration of L19-IL2 in combination with dacarbazine is safe and shows encouraging signs of clinical activity in patients with metastatic melanoma. This combination therapy is currently evaluated in a randomized phase II trial with patients with metastatic melanoma.

References

	Year	Citations

Page 1